Show simple item record

dc.contributor.authorMcDonald, Fen_US
dc.contributor.authorDe Waele, Men_US
dc.contributor.authorHendriks, LELen_US
dc.contributor.authorFaivre-Finn, Cen_US
dc.contributor.authorDingemans, A-MCen_US
dc.contributor.authorVan Schil, PEen_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2018-02-19T11:05:12Z
dc.date.issued2017-01en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/28049169en_US
dc.identifier13993003.00764-2016en_US
dc.identifier.citationEur Respir J, 2017, 49 (1)en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1264
dc.identifier.eissn1399-3003en_US
dc.identifier.doi10.1183/13993003.00764-2016en_US
dc.description.abstractThe incidence of stage I and II nonsmall cell lung cancer is likely to increase with the ageing population and introduction of screening for high-risk individuals. Optimal management requires multidisciplinary collaboration. Local treatments include surgery and radiotherapy and these are currently combined with (neo)adjuvant chemotherapy in specific cases to improve long-term outcome. Targeted therapies and immunotherapy may also become important therapeutic modalities in this patient group. For resectable disease in patients with low cardiopulmonary risk, complete surgical resection with lobectomy remains the gold standard. Minimally invasive techniques, conservative and sublobar resections are suitable for a subset of patients. Data are emerging that radiotherapy, especially stereotactic body radiation therapy, is a valid alternative in compromised patients who are high-risk candidates for surgery. Whether this is also true for good surgical candidates remains to be evaluated in randomised trials. In specific subgroups adjuvant chemotherapy has been shown to prolong survival; however, patient selection remains important. Neoadjuvant chemotherapy may yield similar results as adjuvant chemotherapy. The role of targeted therapies and immunotherapy in early stage nonsmall cell lung cancer has not yet been determined and results of randomised trials are awaited.en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectCarcinoma, Non-Small-Cell Lungen_US
dc.subjectChemotherapy, Adjuvanten_US
dc.subjectCombined Modality Therapyen_US
dc.subjectDisease Managementen_US
dc.subjectHumansen_US
dc.subjectLung Neoplasmsen_US
dc.subjectMeta-Analysis as Topicen_US
dc.subjectNeoplasm Stagingen_US
dc.subjectPneumonectomyen_US
dc.subjectRadiosurgeryen_US
dc.subjectRandomized Controlled Trials as Topicen_US
dc.titleManagement of stage I and II nonsmall cell lung cancer.en_US
dc.typeJournal Article
dcterms.dateAccepted2016-10-04en_US
rioxxterms.versionofrecord10.1183/13993003.00764-2016en_US
rioxxterms.licenseref.startdate2017-01en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfEur Respir Jen_US
pubs.issue1en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished onlineen_US
pubs.volume49en_US
pubs.embargo.termsNot knownen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record